B-cell-targeted therapy for lupus-associated autoimmune haemolytic anaemia: similar response to conventional treatment

Design

Multicampus retrospective cohort, 2020 to 2026

Population

70 patients with first-episode lupus-associated warm autoimmune haemolytic anaemia (27 conventional, 43 B-cell-targeted)

Primary outcome

Six-month overall response rate (complete or partial)

Effect

89.7% versus 85.7% (OR 1.45, 95% CI 0.19 to 9.61, P = 0.687)

A multicampus retrospective cohort screened 246 lupus admissions and included 70 patients with first-episode warm autoimmune haemolytic anaemia, haemoglobin below 90 g/L and laboratory haemolysis. Twenty-seven received conventional glucocorticoid-based therapy and 43 received B-cell-targeted therapy with rituximab, belimumab or telitacicept.

Six-month overall response was 89.7% with B-cell-targeted therapy and 85.7% with conventional treatment (odds ratio 1.45, 95% CI 0.19 to 9.61; P = 0.687). Complete response was 61.5% versus 42.9%. At one month the prednisone-equivalent dose was lower with B-cell-targeted therapy (40.0 versus 50.0 mg/day). Twelve-month response was 89.3% versus 73.7% without a significant difference in relapse-free survival. Within six months 13 inpatient adverse-event episodes were recorded, including fatal events. All seven patients on telitacicept who could be evaluated responded.

The groups differed at baseline, with the B-cell group younger and with higher lupus activity, and the interval around the odds ratio is very wide. The authors call the numerically better complete response and earlier steroid reduction exploratory.

• Six-month overall response was 89.7% versus 85.7%, not significantly different.
• Complete response was numerically higher with B-cell-targeted therapy.
• Prednisone dose at one month was lower with B-cell-targeted therapy.
• Only 70 patients, with unequal groups and wide intervals.
• Consider B-cell-targeted therapy for refractory or steroid-sparing needs, not as proven better.

Why it matters

It gives some real-world data for a rare complication where trials are unlikely.

Don't overread it

A retrospective cohort of 70 patients with different baselines cannot show that either strategy is better.

The statistics, in plain English

An odds ratio of 1.45 with an interval from 0.19 to 9.61 means the data are compatible with a large benefit or a large harm. With 27 and 43 patients, a real difference could easily be missed.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.